Human leukocyte antigen class II DRB1*1302 allele protects against cervical cancer: At which step of multistage carcinogenesis?

Koji Matsumoto, Hiroo Maeda, Akinori Oki, Naoyoshi Takatsuka, Toshiharu Yasugi, Reiko Furuta, Ranko Hirata, Akira Mitsuhashi, Kei Kawana, Takuma Fujii, Takashi Iwata, Yasuo Hirai, Masatoshi Yokoyama, Nobuo Yaegashi, Yoh Watanabe, Yutaka Nagai, Hiroyuki Yoshikawa

研究成果: Article

6 引用 (Scopus)

抄録

We investigated the role of human leukocyte antigen (HLA) class II alleles in multistage cervical carcinogenesis. Cross-sectional analysis for HLA association with cervical cancer included 1253 Japanese women: normal cytology (NL, n = 341), cervical intraepithelial neoplasia grade 1 (CIN1, n = 505), CIN grade 2 or 3 (CIN2/3, n = 96), or invasive cervical cancer (ICC, n = 311). The HLA class II allele frequencies were compared by Fisher's exact test or the χ2-test. The Bonferroni adjustment corrected for multiple comparisons. Among the study subjects, 454 women with low-grade squamous intraepithelial lesion cytology were prospectively monitored by cytology and colposcopy every 3-4 months to analyze cumulative risk of CIN3 within the next 10 years in relation to HLA class II alleles. HLA class II DRB1*1302 allele frequency was similar between women with NL (11.7%) and CIN1 (11.9%), but significantly decreased to 5.2% for CIN2/3 and 5.8% for ICC (P = 0.0003). Correction for multiple testing did not change this finding. In women with low-grade squamous intraepithelial lesion cytology, the cumulative risk of CIN3 diagnosed within 10 years was significantly reduced among DRB1*1302-positive women (3.2% vs. 23.7%, P = 0.03). In conclusion, the two different types of analysis in this single study showed the protective effect of the DRB1*1302 allele against progression from CIN1 to CIN2/3.

元の言語English
ページ(範囲)1448-1454
ページ数7
ジャーナルCancer science
106
発行部数10
DOI
出版物ステータスPublished - 01-10-2015

Fingerprint

HLA Antigens
Uterine Cervical Neoplasms
Carcinogenesis
Alleles
Cell Biology
Gene Frequency
Colposcopy
Cervical Intraepithelial Neoplasia
Cross-Sectional Studies
Squamous Intraepithelial Lesions of the Cervix

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Matsumoto, K., Maeda, H., Oki, A., Takatsuka, N., Yasugi, T., Furuta, R., ... Yoshikawa, H. (2015). Human leukocyte antigen class II DRB1*1302 allele protects against cervical cancer: At which step of multistage carcinogenesis? Cancer science, 106(10), 1448-1454. https://doi.org/10.1111/cas.12760
Matsumoto, Koji ; Maeda, Hiroo ; Oki, Akinori ; Takatsuka, Naoyoshi ; Yasugi, Toshiharu ; Furuta, Reiko ; Hirata, Ranko ; Mitsuhashi, Akira ; Kawana, Kei ; Fujii, Takuma ; Iwata, Takashi ; Hirai, Yasuo ; Yokoyama, Masatoshi ; Yaegashi, Nobuo ; Watanabe, Yoh ; Nagai, Yutaka ; Yoshikawa, Hiroyuki. / Human leukocyte antigen class II DRB1*1302 allele protects against cervical cancer : At which step of multistage carcinogenesis?. :: Cancer science. 2015 ; 巻 106, 番号 10. pp. 1448-1454.
@article{7d89360d65e9420e8a01f72db55b819c,
title = "Human leukocyte antigen class II DRB1*1302 allele protects against cervical cancer: At which step of multistage carcinogenesis?",
abstract = "We investigated the role of human leukocyte antigen (HLA) class II alleles in multistage cervical carcinogenesis. Cross-sectional analysis for HLA association with cervical cancer included 1253 Japanese women: normal cytology (NL, n = 341), cervical intraepithelial neoplasia grade 1 (CIN1, n = 505), CIN grade 2 or 3 (CIN2/3, n = 96), or invasive cervical cancer (ICC, n = 311). The HLA class II allele frequencies were compared by Fisher's exact test or the χ2-test. The Bonferroni adjustment corrected for multiple comparisons. Among the study subjects, 454 women with low-grade squamous intraepithelial lesion cytology were prospectively monitored by cytology and colposcopy every 3-4 months to analyze cumulative risk of CIN3 within the next 10 years in relation to HLA class II alleles. HLA class II DRB1*1302 allele frequency was similar between women with NL (11.7{\%}) and CIN1 (11.9{\%}), but significantly decreased to 5.2{\%} for CIN2/3 and 5.8{\%} for ICC (P = 0.0003). Correction for multiple testing did not change this finding. In women with low-grade squamous intraepithelial lesion cytology, the cumulative risk of CIN3 diagnosed within 10 years was significantly reduced among DRB1*1302-positive women (3.2{\%} vs. 23.7{\%}, P = 0.03). In conclusion, the two different types of analysis in this single study showed the protective effect of the DRB1*1302 allele against progression from CIN1 to CIN2/3.",
author = "Koji Matsumoto and Hiroo Maeda and Akinori Oki and Naoyoshi Takatsuka and Toshiharu Yasugi and Reiko Furuta and Ranko Hirata and Akira Mitsuhashi and Kei Kawana and Takuma Fujii and Takashi Iwata and Yasuo Hirai and Masatoshi Yokoyama and Nobuo Yaegashi and Yoh Watanabe and Yutaka Nagai and Hiroyuki Yoshikawa",
year = "2015",
month = "10",
day = "1",
doi = "10.1111/cas.12760",
language = "English",
volume = "106",
pages = "1448--1454",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "10",

}

Matsumoto, K, Maeda, H, Oki, A, Takatsuka, N, Yasugi, T, Furuta, R, Hirata, R, Mitsuhashi, A, Kawana, K, Fujii, T, Iwata, T, Hirai, Y, Yokoyama, M, Yaegashi, N, Watanabe, Y, Nagai, Y & Yoshikawa, H 2015, 'Human leukocyte antigen class II DRB1*1302 allele protects against cervical cancer: At which step of multistage carcinogenesis?', Cancer science, 巻. 106, 番号 10, pp. 1448-1454. https://doi.org/10.1111/cas.12760

Human leukocyte antigen class II DRB1*1302 allele protects against cervical cancer : At which step of multistage carcinogenesis? / Matsumoto, Koji; Maeda, Hiroo; Oki, Akinori; Takatsuka, Naoyoshi; Yasugi, Toshiharu; Furuta, Reiko; Hirata, Ranko; Mitsuhashi, Akira; Kawana, Kei; Fujii, Takuma; Iwata, Takashi; Hirai, Yasuo; Yokoyama, Masatoshi; Yaegashi, Nobuo; Watanabe, Yoh; Nagai, Yutaka; Yoshikawa, Hiroyuki.

:: Cancer science, 巻 106, 番号 10, 01.10.2015, p. 1448-1454.

研究成果: Article

TY - JOUR

T1 - Human leukocyte antigen class II DRB1*1302 allele protects against cervical cancer

T2 - At which step of multistage carcinogenesis?

AU - Matsumoto, Koji

AU - Maeda, Hiroo

AU - Oki, Akinori

AU - Takatsuka, Naoyoshi

AU - Yasugi, Toshiharu

AU - Furuta, Reiko

AU - Hirata, Ranko

AU - Mitsuhashi, Akira

AU - Kawana, Kei

AU - Fujii, Takuma

AU - Iwata, Takashi

AU - Hirai, Yasuo

AU - Yokoyama, Masatoshi

AU - Yaegashi, Nobuo

AU - Watanabe, Yoh

AU - Nagai, Yutaka

AU - Yoshikawa, Hiroyuki

PY - 2015/10/1

Y1 - 2015/10/1

N2 - We investigated the role of human leukocyte antigen (HLA) class II alleles in multistage cervical carcinogenesis. Cross-sectional analysis for HLA association with cervical cancer included 1253 Japanese women: normal cytology (NL, n = 341), cervical intraepithelial neoplasia grade 1 (CIN1, n = 505), CIN grade 2 or 3 (CIN2/3, n = 96), or invasive cervical cancer (ICC, n = 311). The HLA class II allele frequencies were compared by Fisher's exact test or the χ2-test. The Bonferroni adjustment corrected for multiple comparisons. Among the study subjects, 454 women with low-grade squamous intraepithelial lesion cytology were prospectively monitored by cytology and colposcopy every 3-4 months to analyze cumulative risk of CIN3 within the next 10 years in relation to HLA class II alleles. HLA class II DRB1*1302 allele frequency was similar between women with NL (11.7%) and CIN1 (11.9%), but significantly decreased to 5.2% for CIN2/3 and 5.8% for ICC (P = 0.0003). Correction for multiple testing did not change this finding. In women with low-grade squamous intraepithelial lesion cytology, the cumulative risk of CIN3 diagnosed within 10 years was significantly reduced among DRB1*1302-positive women (3.2% vs. 23.7%, P = 0.03). In conclusion, the two different types of analysis in this single study showed the protective effect of the DRB1*1302 allele against progression from CIN1 to CIN2/3.

AB - We investigated the role of human leukocyte antigen (HLA) class II alleles in multistage cervical carcinogenesis. Cross-sectional analysis for HLA association with cervical cancer included 1253 Japanese women: normal cytology (NL, n = 341), cervical intraepithelial neoplasia grade 1 (CIN1, n = 505), CIN grade 2 or 3 (CIN2/3, n = 96), or invasive cervical cancer (ICC, n = 311). The HLA class II allele frequencies were compared by Fisher's exact test or the χ2-test. The Bonferroni adjustment corrected for multiple comparisons. Among the study subjects, 454 women with low-grade squamous intraepithelial lesion cytology were prospectively monitored by cytology and colposcopy every 3-4 months to analyze cumulative risk of CIN3 within the next 10 years in relation to HLA class II alleles. HLA class II DRB1*1302 allele frequency was similar between women with NL (11.7%) and CIN1 (11.9%), but significantly decreased to 5.2% for CIN2/3 and 5.8% for ICC (P = 0.0003). Correction for multiple testing did not change this finding. In women with low-grade squamous intraepithelial lesion cytology, the cumulative risk of CIN3 diagnosed within 10 years was significantly reduced among DRB1*1302-positive women (3.2% vs. 23.7%, P = 0.03). In conclusion, the two different types of analysis in this single study showed the protective effect of the DRB1*1302 allele against progression from CIN1 to CIN2/3.

UR - http://www.scopus.com/inward/record.url?scp=84945589491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945589491&partnerID=8YFLogxK

U2 - 10.1111/cas.12760

DO - 10.1111/cas.12760

M3 - Article

C2 - 26235935

AN - SCOPUS:84945589491

VL - 106

SP - 1448

EP - 1454

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 10

ER -